Overview

A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether multiple doses of Talampanel increase the QT interval when compared to placebo
Phase:
Phase 1
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries
Collaborator:
Cetero Research, San Antonio
Treatments:
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination